Illustration: Assistant editor Kathy Wong for Endpoints News
Investors have pulled back from the biotech industry in recent months. But not Pablo Legorreta, who quietly pioneered a drug development niche that’s in demand …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
